ReviewFrontiers in immunology2026
Passenger lymphocyte syndrome following organ and stem cell transplantation: current insights and clinical implications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Passenger lymphocyte syndrome (PLS) is an alloimmune complication of ABO-mismatched solid organ or hematopoietic stem cell transplantation characterized by the production of antibodies by donor-derived B lymphocytes against the recipient's red blood cell antigens. Its incidence, risk factors, and management remain poorly defined because many cases are subclinical, and most reports are case based. This study aimed to summarize the available literature on PLS, focusing on its incidence, immunohematologic mechanisms, clinical features, and management. Methods: We systematically searched PubMed and Embase for publications up to August 2025 and included case reports, case series, and cohort studies describing PLS after kidney, liver, lung, intestinal, and hematopoietic stem cell transplantation. Data on epidemiology, ABO constellation, antibody specificity, clinical presentation, treatment, and outcomes were extracted. Results: We identified 64 studies reporting 135 cases of PLS. All were observational comprising 78% case reports/series and 22% retrospective cohort. 17 studies involved kidney transplantation, 23 liver, 7 lung, 6 intestinal, 1 heart, and 10 hematopoietic stem cell transplantations. The reported incidence ranged from approximately 9% in kidney to approximately 30-40% in liver and over 50% in lung transplantation. ABO isoagglutinins were the predominant antibodies, while Rh, Kidd, Kell, and Lewis specificities were also implicated. Most cases presented within 1-3 weeks post-transplant with abrupt hemolysis, which was usually self-limiting; however, severe cases required transfusion support, plasma exchange, or rituximab. Mortality was rare but occurred in delayed or fulminant cases. Conclusions: PLS is an under-recognized post-transplant complication with variable incidence and outcomes across organ types. Standardized diagnostic criteria, evidence-based management strategies, and multicenter studies are needed to guide clinical practice and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.